API | eptinezumab

eptinezumab (Vyepti) Report issue

Biologics mAb Approved ^FDA

AACT

Active Ingredient History

NOW

Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion every 3 months. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
eptinezumab

More Chemistry

Pharmacology

Mechanisms of Action:
- Calcitonin gene-related peptide 1 (Homo sapiens) ^UniProt
- Calcitonin gene-related peptide 2 (Homo sapiens) ^UniProt
- Calcitonin gene-related peptide 1 (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

Drug Pricing (per unit)

United States

$1119.0800 - $1479.9800

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

eptinezumab

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (1)

Migraine Disorders (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Cluster Headache (Phase 3)

Diabetic Neuropathies (Phase 2)

Headache Disorders, Secondary (Phase 4)

Healthy Volunteers (Phase 1)

Migraine Disorders (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 24
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue